Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/32335
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSerrano Afonso, Ancor-
dc.contributor.authorPérez hernández, Concepción-
dc.contributor.authorOchoa Mazarro, Dolores-
dc.contributor.authorRomán Martínez, Manuel-
dc.contributor.authorFailde Martínez, Inmaculada-
dc.contributor.authorMontes Pérez, Antonio-
dc.contributor.authorLópez Pais, Pablo-
dc.contributor.authorCánovas Martínez, Luz-
dc.contributor.authorRevuelta Rizo, Miren-
dc.contributor.authorPadilla del Rey, María Luz-
dc.contributor.authorPeiró, Ana-
dc.contributor.authorAberasturi Fueyo, Teresa-
dc.contributor.authorMargarit Ferrí, César-
dc.contributor.authorRojo Rodríguez, Elena-
dc.contributor.authorMendiola de la Osa, Agustín-
dc.contributor.authorMuñoz Martinez, Manuel José-
dc.contributor.authorDomínguez Bronchal, María Jesús-
dc.contributor.authorHerrero Trujillano, Manuel-
dc.contributor.authorCid Calzada, José-
dc.contributor.authorFabregat-Cid, Gustavo-
dc.contributor.authorHernández-Cádiz, María José-
dc.contributor.authorMareque Ortega, Manuel-
dc.contributor.authorGómez-Caro Álvarez Palencia, Leticia-
dc.contributor.authorMayoral Rojals, Víctor-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-06-25T09:04:59Z-
dc.date.available2024-06-25T09:04:59Z-
dc.date.created2021-07-
dc.identifier.citationMedicine Volume 100, Issue 30, Pages e26725es_ES
dc.identifier.issn0025-7974-
dc.identifier.urihttps://hdl.handle.net/11000/32335-
dc.description.abstractIn patients with coronavirus disease 2019 (COVID-19) infection, common drugs may exacerbate symptoms and negatively impact outcomes. However, the role of chronic medications on COVID-19 effects remains poorly understood. We hypothesized that certain chronic pain medications would influence outcomes in patients with COVID-19. The main aim is to assess the effect of these medications on the course of the disease in COVID-19 patients. Secondary aims are to compare disease severity and outcomes in patients with COVID-19 receiving chronic treatment with analgesics or other medications versus untreated patients and to determine prevalence of chronic pain medications in specific subgroups of hospitalized patients for COVID-19. Multicenter case-population study in 15 care centers for patients ≥18 years of age diagnosed and hospitalized with COVID-19. Controls will include patients treated at participating centers for chronic pain during the six-month period prior to March 15th, 2020. Each case will be age- and sex-matched to 10 controls. Patients will be grouped according to disease severity criteria. The primary outcome measures in patients admitted for COVID-19 will be: 1. statistical association between chronic pain medication and disease severity; 2.association between chronic pain treatment and survival. Secondary outcome measures include: 1.prevalence of chronic pain medications in patients with COVID-19 by age and sex; 2.prevalence of chronic pain medications in patients with COVID-19 vs controls. Patients and controls will be paired by age, sex, and geographic residence. Odds ratios with 95% confidence intervals will be calculated to determine the association between each drug and clinical status. Univariate and multivariate analyses will be performed. This is a study protocol. Data is actually being gathered and results are yet not achieved. There is no numerical data presented, so the conclusions cannot be considered solid at this point. Pain medications are likely to influence severity of COVID-19 and patient survival. Identifying those medications that are most closely associated with severe COVID-19 will provide clinicians with valuable data to guide treatment and reduce mortality rates and the long-term sequelae of the disease.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent7es_ES
dc.language.isoenges_ES
dc.publisherNLM (Medline)es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectanalgesicses_ES
dc.subjectchronic paines_ES
dc.subjectcoronavirus disease 2019es_ES
dc.subjectglucocorticoidses_ES
dc.subjectnon-steroidal anti-inflammatory drugses_ES
dc.subjectopioidses_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::615 - Farmacología. Terapéutica. Toxicología. Radiologíaes_ES
dc.titleAssociation between chronic pain medications and the severity and mortality of COVID-19: Study protocol for a case-population studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1097/MD.0000000000026725es_ES
Appears in Collections:
Artículos Farmacología, Pediatría y Química Orgánica


Thumbnail

View/Open:
 Association between chronic pain medications.pdf

239,07 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???